Home LiteratureArticle Details
PMID: 3084421 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay.

Japanese journal of cancer research : Gann ·Vol. 77 ·No. 3 ·1986-03-00 ·Pages 312-8

Lee YC, Saijo N, Sasaki Y, Takahashi H, Sakurai M, Ishihara J, Sano T, Hoshi A, Chen KM, Hamburger AW

Abstract

The antitumor effects of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide were examined in human pulmonary adenocarcinoma cell lines by human tumor clonogenic assay. Different tumor cell lines (PC-9, PC-13 and PC-14) that originated from the same histological cell type responded quite variably to simultaneous and/or sequential therapy. The antitumor effects of various sequential combinations of cisplatin, vindesine and etoposide depended strongly on the nature of the individual tumor cell line tested.

MeSH Terms
Adenocarcinoma/drug therapy Antineoplastic Combined Chemotherapy Protocols/therapeutic use Cell Line Cisplatin/administration & dosage Colony-Forming Units Assay Etoposide/administration & dosage Humans Lung Neoplasms/drug therapy Tumor Stem Cell Assay Vindesine/administration & dosage
Chemicals
Etoposide Cisplatin Vindesine
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Lee Y C
Saijo N
Sasaki Y
Takahashi H
Sakurai M
Ishihara J
Sano T
Hoshi A
Chen K M
Hamburger A W
Article Info
Journal
Japanese journal of cancer research : Gann
Abbr.
Jpn J Cancer Res
ISSN
0910-5050
Published
1986-03-00
Pages
312-8
Language
English
Region
Japan
NLM ID
8509412
Subset
IM
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]